Literature DB >> 24100235

Pseudovirus mimics cell entry and trafficking of the human polyomavirus JCPyV.

Gretchen V Gee1, Bethany A O'Hara, Aaron Derdowski, Walter J Atwood.   

Abstract

The normally asymptomatic human polyomavirus, JCPyV, is the causative agent of a rare but fatal demyelinating disease known as progressive multifocal leukoencephalopathy (PML). Individuals at risk for developing PML include those with AIDS, with other underlying immunosuppressive diseases, and in patients treated with immunomodulatory regimens. Drugs to prevent viral reactivation in the setting of immunosuppression or immunomodulation could be used to sustain lives. Development of such drugs has been impeded by the difficulty of growing and studying the virus. We sought to develop a more efficient method for screening drugs that inhibit viral infection. Pseudovirus models have been developed which may be of use in pharmaceutical research. The use of pseudoviruses as models for viral infection is dependent on them using similar pathways for infection as virus. We screened known inhibitors of viral entry for their ability to block pseudovirus infection. Here we show that the pseudovirus based on the human polyomavirus JCPyV recapitulates virus binding, entry and trafficking. This system can be used for high-throughput screening of antiviral drugs.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  JC polyomavirus; Natalizumab; Progressive multifocal leukoencephalopathy; Pseudovirus; Virus entry

Mesh:

Substances:

Year:  2013        PMID: 24100235      PMCID: PMC3849699          DOI: 10.1016/j.virusres.2013.09.030

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  35 in total

Review 1.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

2.  Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).

Authors:  Niklas Schmedt; Frank Andersohn; Edeltraut Garbe
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-07-22       Impact factor: 2.890

3.  Glial cell-specific regulation of the JC virus early promoter by large T antigen.

Authors:  H S Kim; N M Goncalves; J W Henson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.

Authors:  Johannis A van Rossum; Anke Vennegoor; Lisanne Balk; Bernard M Uitdehaag; Chris H Polman; Joep Killestein
Journal:  Mult Scler       Date:  2013-07-04       Impact factor: 6.312

Review 5.  Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  Michael W Ferenczy; Leslie J Marshall; Christian D S Nelson; Walter J Atwood; Avindra Nath; Kamel Khalili; Eugene O Major
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

6.  The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.

Authors:  Christian D S Nelson; Aaron Derdowski; Melissa S Maginnis; Bethany A O'Hara; Walter J Atwood
Journal:  Virology       Date:  2012-04-18       Impact factor: 3.616

Review 7.  Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.

Authors:  Kelly J Baldwin; Jeffery P Hogg
Journal:  Curr Opin Neurol       Date:  2013-06       Impact factor: 5.710

8.  Quantitation of human seroresponsiveness to Merkel cell polyomavirus.

Authors:  Diana V Pastrana; Yanis L Tolstov; Jürgen C Becker; Patrick S Moore; Yuan Chang; Christopher B Buck
Journal:  PLoS Pathog       Date:  2009-09-11       Impact factor: 6.823

9.  Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.

Authors:  Yanis L Tolstov; Diana V Pastrana; Huichen Feng; Jürgen C Becker; Frank J Jenkins; Stergios Moschos; Yuan Chang; Christopher B Buck; Patrick S Moore
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

10.  Contrasting roles of endosomal pH and the cytoskeleton in infection of human glial cells by JC virus and simian virus 40.

Authors:  Aarthi Ashok; Walter J Atwood
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  13 in total

1.  The Greater Affinity of JC Polyomavirus Capsid for α2,6-Linked Lactoseries Tetrasaccharide c than for Other Sialylated Glycans Is a Major Determinant of Infectivity.

Authors:  Luisa J Ströh; Melissa S Maginnis; Bärbel S Blaum; Christian D S Nelson; Ursula Neu; Gretchen V Gee; Bethany A O'Hara; Nasim Motamedi; Daniel DiMaio; Walter J Atwood; Thilo Stehle
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

2.  Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus.

Authors:  Bethany A O'Hara; Gretchen V Gee; Walter J Atwood; Sheila A Haley
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

3.  Gallic acid-based small-molecule inhibitors of JC and BK polyomaviral infection.

Authors:  Bethany A O'Hara; Chamila Rupasinghe; Achani Yatawara; Gabriel Gaidos; Dale F Mierke; Walter J Atwood
Journal:  Virus Res       Date:  2014-06-21       Impact factor: 3.303

Review 4.  In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection.

Authors:  Heidi Barth; Morgane Solis; Wallys Kack-Kack; Eric Soulier; Aurélie Velay; Samira Fafi-Kremer
Journal:  Viruses       Date:  2016-10-22       Impact factor: 5.048

5.  High-Throughput Characterization of Viral and Cellular Protein Expression Patterns During JC Polyomavirus Infection.

Authors:  Jeanne K DuShane; Michael P Wilczek; Mason A Crocker; Melissa S Maginnis
Journal:  Front Microbiol       Date:  2019-04-17       Impact factor: 5.640

6.  JC Polyomavirus Uses Extracellular Vesicles To Infect Target Cells.

Authors:  Jenna Morris-Love; Gretchen V Gee; Bethany A O'Hara; Benedetta Assetta; Abigail L Atkinson; Aisling S Dugan; Sheila A Haley; Walter J Atwood
Journal:  mBio       Date:  2019-04-09       Impact factor: 7.867

7.  Trichodysplasia spinulosa-Associated Polyomavirus Uses a Displaced Binding Site on VP1 to Engage Sialylated Glycolipids.

Authors:  Luisa J Ströh; Gretchen V Gee; Bärbel S Blaum; Aisling S Dugan; Mariet C W Feltkamp; Walter J Atwood; Thilo Stehle
Journal:  PLoS Pathog       Date:  2015-08-24       Impact factor: 6.823

8.  Interaction between Simian Virus 40 Major Capsid Protein VP1 and Cell Surface Ganglioside GM1 Triggers Vacuole Formation.

Authors:  Yong Luo; Nasim Motamedi; Thomas G Magaldi; Gretchen V Gee; Walter J Atwood; Daniel DiMaio
Journal:  MBio       Date:  2016-03-22       Impact factor: 7.867

9.  Characterization of human papillomavirus type 16 pseudovirus containing histones.

Authors:  Hyoung Jin Kim; Hye-Lim Kwag; Hong-Jin Kim
Journal:  BMC Biotechnol       Date:  2016-08-27       Impact factor: 2.563

10.  Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector.

Authors:  Chun-Nun Chao; Yu-Hsuan Yang; Mu-Sheng Wu; Ming-Chieh Chou; Chiung-Yao Fang; Mien-Chun Lin; Chien-Kuo Tai; Cheng-Huang Shen; Pei-Lain Chen; Deching Chang; Meilin Wang
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.